Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00351884
Recruitment Status : Completed
First Posted : July 13, 2006
Last Update Posted : November 18, 2016
Information provided by:

Brief Summary:
Vildagliptin is an oral anti-diabetic agent. This is a 24-week study to assess the efficacy on HbA1c of 100 mg vildagliptin once daily as compared to placebo as add-on to metformin in patients with type 2 diabetes inadequately controlled with metformin.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Drug: Vildagliptin AM Drug: vildagliptin pm Drug: placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 370 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 100 MG QD to Placebo as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Study Start Date : May 2006
Actual Primary Completion Date : November 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Metformin

Arm Intervention/treatment
Experimental: vildagliptin am Drug: Vildagliptin AM
Experimental: vildagliptin pm Drug: vildagliptin pm
Placebo Comparator: placebo Drug: placebo

Primary Outcome Measures :
  1. Change from baseline in HbA1c at 24 weeks [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. Safety of vildagliptin in combination with metformin during 24 weeks of treatment [ Time Frame: 24 weeks ]
  2. Change from baseline in fasting plasma glucose at 24 weeks [ Time Frame: 24 weeks ]
  3. Patients with endpoint HbA1c < 7% after 24 weeks [ Time Frame: 24 weeks ]
  4. Patients with reduction in HbA1c greater than or equal to 0.7% after 24 weeks [ Time Frame: 24 weeks ]
  5. Change from baseline in body weight at 24 weeks [ Time Frame: 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 78 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients on metformin for at least three months and on a stable dose of at least 1500 mg daily for a minimum of 4 weeks prior to visit 1
  • Body mass index in the range 22-40
  • Blood glucose criteria must be met

Exclusion Criteria:

  • Pregnancy or lactation
  • History of type 1 diabetes
  • Evidence of significant diabetic complications

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00351884

United States, New Jersey
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
Novartis Investigative Site
Investigative Centers, Germany
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Additional Information:
Publications of Results:
Responsible Party: External Affairs, Novartis Pharmaceuticals Corporation Identifier: NCT00351884     History of Changes
Other Study ID Numbers: CLAF237A23103
First Posted: July 13, 2006    Key Record Dates
Last Update Posted: November 18, 2016
Last Verified: November 2016

Keywords provided by Novartis:
Type 2 diabetes
Hemoglobin A1c

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action